Gastrointestinal Stromal Tumors - Pipeline Insight, 2024

This “Gastrointestinal Stromal Tumors - Pipeline Insight, 2024,” report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Gastrointestinal Stromal Tumors Understanding

Gastrointestinal Stromal Tumors: Overview

Gastrointestinal stromal tumors (GISTs) are among a group of cancers known as sarcomas. GISTs belong to the family of sarcomas, which are malignant tumors that arise from various tissues, including fat, muscle, nerves, cartilage, bone, blood vessels, and lymphatic vessels. This distinguishes sarcomas from carcinomas, which arise from the lining of organs/tissues (e.g., lung, colon, breast, prostate, and pancreas), lymphomas, which arise from immune cells in lymph nodes, and leukemias, which arise from immune cells in the bone marrow. GIST can present with a wide spectrum of subjective symptoms, such as nausea, early satiety, bloating, and weight loss. Patients can also experience objective signs of a tumor, such as anemia (low red blood cell count) or a lump in the abdomen. These signs and symptoms depend on the tumor location (e.g., stomach versus rectum), size, and pattern of growth.

Gastrointestinal Stromal Tumors - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastrointestinal Stromal Tumors pipeline landscape is provided which includes the disease overview and Gastrointestinal Stromal Tumors treatment guidelines. The assessment part of the report embraces, in depth Gastrointestinal Stromal Tumors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastrointestinal Stromal Tumors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Gastrointestinal Stromal Tumors R&D. The therapies under development are focused on novel approaches to treat/improve Gastrointestinal Stromal Tumors.

Gastrointestinal Stromal Tumors Emerging Drugs Chapters

This segment of the Gastrointestinal Stromal Tumors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gastrointestinal Stromal Tumors Emerging Drugs

Famitinib: Jiangsu Hengrui Medicine Famitinib, an orally active, small molecule, is a tyrosine kinase inhibitor against multiple targets, including vascular endothelial growth factor receptor 2/3, platelet-derived growth factor receptor, and stem cell factor receptor (c-kit). Jiangsu Hengrui Medicine Co is developing famitinib against a wide variety of advanced-stage solid cancers. The drug is currently in phase III stage of clinical trial evaluation to treat Gastrointestinal StromalTumors.

Nilotinib: Novartis Tasigna (nilotinib hydrochloride monohydrate) is an orally available signal transduction inhibitor of the Bcr-Abl kinase, c-kit and Platelet Derived Growth Factor (PDGF), all of which play a role in cell proliferation, cell migration, and angiogenesis. Tasigna is specifically indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to prior therapy that included imatinib. The drug is currently being investigated in Phase II clinical trial to evaluate its potential for the treatment of gastrointestinal stromaltumors.

THE-630: Theseus Pharmaceuticals THE-630 is a pan-variant inhibitor of the receptor tyrosine kinase KIT. It is designed for patients with advanced GIST whose cancer has developed resistance to earlier lines of therapy by accruing mutations that render those therapies ineffective. In GIST, these mutations occur most often in the KIT protein, where a patient can have multiple KIT mutations simultaneously, leading to complex disease heterogeneity. In preclinical studies, THE-630 demonstrated potent in vitro and in vivo activity against all major classes of KIT activating and resistance mutations in GIST. Moreover, THE-630 achieved predicted pan-variant KIT inhibitory blood concentrations at tolerable doses and was associated with significant anti-tumor activity. Theseus Pharmaceuticals is currently conducting Phase I/II study to evaluate lead candidate, THE-630, in patients with advanced gastrointestinal stromal tumors (GIST).

DS 6157: Daiichi Sankyo Company DS-6157 is a potential first-in-class GPR20 targeting ADC and the fifth DXd ADC in the oncology pipeline of Daiichi Sankyo to enter clinical development. ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy (“payload”) to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells. Designed utilizing Daiichi Sankyo’s proprietary DXd ADC technology, DS-6157 is comprised of a humanized anti-GPR20 monoclonal antibody, which is attached to a novel topoisomerase I inhibitor payload by a tetrapeptide-based linker. The drug is currently in Phase I stage of clinical trial evaluation to treat Gastrointestinal StromalTumors.

Gastrointestinal Stromal Tumors: Therapeutic Assessment

This segment of the report provides insights about the different Gastrointestinal Stromal Tumors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Gastrointestinal Stromal Tumors

There are approx. 25+ key companies which are developing the therapies for Gastrointestinal Stromal Tumors. The companies which have their Gastrointestinal Stromal Tumors drug candidates in the most advanced stage, i.e. phase III include, Jiangsu Hengrui Medicine.

Phases

This report covers around 28+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Gastrointestinal Stromal Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Gastrointestinal Stromal Tumors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastrointestinal Stromal Tumors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastrointestinal Stromal Tumors drugs.

Gastrointestinal Stromal Tumors Report Insights

• Gastrointestinal Stromal Tumors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Gastrointestinal Stromal Tumors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Gastrointestinal Stromal Tumors drugs?
• How many Gastrointestinal Stromal Tumors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gastrointestinal Stromal Tumors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Gastrointestinal Stromal Tumors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Gastrointestinal Stromal Tumors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Jiangsu Hengrui Medicine
• Daiichi Sankyo Company
• Cogent Biosciences
• Advenchen Laboratories
• Chia Tai Tianqing Pharmaceutical Group
• AB Science
• Immunicum AB
• Novartis
• Bristol-Myers Squibb
• Hanmi Pharmaceutical Company Limited
• GlaxoSmithKline
• Ascentage Pharma
• Takeda
• Array BioPharma
• Plexxikon
• Arog Pharmaceuticals
• Xencor, Inc.
• DNAtrix, Inc.
• Onyx Pharmaceuticals
• Exelixis
• Allarity Therapeutics
• Theseus Pharmaceuticals
• IDRx, Inc.
• Allarity Therapeutics

Key Products

• Famitinib
• DS 6157
• PLX9486
• Anlotinib
• Masitinib
• Intuvax
• Dovitinib
• Ipilimumab
• L-carnitine
• Pazopanib
• Nilotinib
• HQP1351
• PDR001
• Ponatinib
• MEK162
• Crenolanib besylate
• XmAb18087
• TNO155
• DNX-2440
• Palbociclib
• Cabozantinib
• Pamufetinib
• THE-630
• IDRX-42

This product will be delivered within 1-3 business days.